VNU cancels IMS deal
This article was originally published in The Tan Sheet
Executive Summary
Dutch publishing company VNU has agreed to terminate the merger with IMS Health after nearly 50% of shareholders voiced opposition to the deal, the Haarlem, Netherlands-based firm announces Nov. 17. The deal would have needed approval from more than half of shareholders in order to go through, VNU explained. The company will pay a termination fee of $15 mil. to IMS due to the falling-through of the deal. VNU announced the $7 bil. merger plans in July, but vacillated on the acquisition during the week of Nov. 7 (1"The Tan Sheet" Nov. 14, 2005, In Brief)...
You may also be interested in...
IMS/VNU merger
VNU is considering amending or terminating its merger agreement with IMS Health, the company says Nov. 7. The two firms agreed to the $7 bil. merger in July and expected the deal to close in early 2006 (1"The Tan Sheet" July 18, 2003, p. 9). However, Netherlands-based VNU says "shareholders claiming to represent 48% of VNU's outstanding shares [said] they would not support the transaction under any circumstances." VNU is AC Nielsen's parent company and provides consumer, marketing and media information to the healthcare industry; IMS Health focuses primarily on Rx healthcare. "Various possible alternatives" have been discussed including the deal's revision, VNU says...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.